Categories: ITPlatformTime
Stentys is listed on the NYSE Euronext [STNT] and offers simple, innovative solutions to interventional cardiologists when treating the challenging disease of their patients. When faced with a situation where choosing the appropriate stent size is not easy, such as in acute myocardial infarction or in bifurcation lesions, the STENTYS platform provides an efficient and elegant new treatment approach. The STENTYS stent can cater for a range of vessel diameters and is able to adapt itself acutely to different diameters along the vessel. It can also continue to expand over time to remain apposed to the vessel, even when there is positive remodelling. Stentys was founded by Gonzague Issenmann and Professor Jacques Seguin. Sofinnova Partners was the first investor in the company.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.10.2010 | - | $31.9M | - |
Mentions in press and media 6
| Date | Title | Description |
| 13.06.2014 | Stentys closes $1.4M acquisition of Cappella’s Peel Away stent delivery device | Stentys said it’s closed the deal on the €1 million ($1.4 million) deal to acquire the Peel Away stent delivery system.
The cash-and-stock deal is the 1st strategic acquisition for Stentys, which makes a line of bare-metal and drug-eluting ... |
| 11.01.2013 | French coronary stent maker aims to take on U.S. rivals with flexible bare metal stent | Because of its flexible nature, the stent does not require the use of a balloon catheter needed by conventional stents to be delivered inside the artery to remove the blood clot formed that results in a heart attack.
The STENTYS Bare Metal ... |
| 28.10.2010 | France’s Stentys raises $31.9M for cardiac stents | “This cash infusion is obviously a very significant event for Stentys, as we now have the means to establish Stentys’ self-apposing stent as the reference treatment for AMI, a $2.3 billion market,” Stentys chairman and co-founder Jacques Se... |
| 19.03.2008 | Life-science briefing: Wednesday, March 19, 2008 | Paris-based Stentys takes $18M for “bifurcated” stents — Stentys, a Paris-based medical device maker, raised $18 million in a second funding round. The company is developing “bifurcated” stents intended to prop open clogged arteries at bloo... |
| - | France’s Stentys raises $31.9M for cardiac stents | Stentys completed an initial public offering worth $31.9 million.
The Paris-based cardiac stent developer’s shares are now listed and traded on the NYSE Euronext Paris exchange under the symbol STNT.
Stentys plans to use the proceeds from t... |
| - | French coronary stent maker aims to take on U.S. rivals with flexible bare metal stent | Conventional coronary stents are made of steel, while some are made of advanced alloys like chromium.
But no matter what they are made of, they are all rigid and are hamstrung by that very fact, believes Gonzague Issenmann, CEO of French st... |
Reviews 0
